fbpx

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

“The Important Role of COVID-19 Therapeutics In A Post-Vaccine World” By Atossa Therapeutics (ATOS)

By John F. Heerdink, Jr.
[social_share_button themes='theme8']

Tribe Public’s Webinar Presentation and Q&A Event which on Tuesday, February 2.

Steven Quay, MD, PhD, CEO & Founder & Kyle Guse CFO of Atossa Therapeutics (NASDAQ: ATOS) delivered a presentation titled “The Important Role of COVID-19 Therapeutics In A Post-Vaccine World.” They also addressed Q&A session at the end of the presentation.

Dr. Quay is an author, entrepreneur, and accomplished physician-scientist that has founded six startups invented seven FDA-approved pharmaceuticals and holds 87 US patents. Over 80 million people have benefited from the medicines he invented. He received his M.D., M.A., and Ph.D. from The University of Michigan. He was a postdoctoral fellow at MIT with Nobel Laureate H. Gobind Khorana and a resident at the Harvard-Massachusetts General Hospital. He was on the faculty of Stanford University School of Medicine for almost a decade.

Atossa Therapeutics (NASDAQ: ATOS), is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need. Atossa’s current focus is on breast cancer and COVID-19. Atossa has two programs to develop therapies to treat COVID-19: One called the COVID-19 HOPE Program which uses AT-H201 for severely ill patients to improve lung function and reduce the amount of time that COVID-19 patients are on ventilators and another called AT-301 Nasal Spray for at-home use immediately following diagnosis of COVID-19 to proactively reduce symptoms of COVID-19 and to slow the infection rate so that a person’s immune system can more effectively fight the virus.

Related Interviews



YOUR GUIDE TO STAYING INFORMED IN THE MARKETS

Subscribe for FREE Email Updates & Access To EXCLUSIVE Research!

Connect with us